TY - JOUR
T1 - Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease
AU - HALT PKD Study Group
AU - Dad, Taimur
AU - Abebe, Kaleab Z.
AU - Bae, K. Ty
AU - Comer, Diane
AU - Torres, Vicente E.
AU - Czarnecki, Peter G.
AU - Schrier, Robert W.
AU - Steinman, Theodore I.
AU - Moore, Charity G.
AU - Chapman, Arlene B.
AU - Kaya, Diana
AU - Tao, Cheng
AU - Braun, William E.
AU - Winklhofer, Franz T.
AU - Brosnahan, Godela
AU - Hogan, Marie C.
AU - Miskulin, Dana C.
AU - Rahbari Oskoui, Frederic
AU - Flessner, Michael F.
AU - Perrone, Ronald D.
N1 - Funding Information:
The investigators thank Gigi Flynn, Robin Woltman, and all of the clinical coordinators at each clinical site for their perseverance and hard work in implementing HALT-PKD. TD is supported by NIDDKT32-DK007777 from the National Institutes of Health National Institute of Diabetes, Digestive and Kidney Diseases. The HALT-PKD study was supported by cooperative agreements from the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (DK62408, DK62401, DK62410, DK62402, and DK62411). The HALT-PKD study and this publication were also supported by grants from the National Center for Research Resources (RR000039 Emory, RR000051 Colorado, RR00585 Mayo, RR000054 Tufts Medical Center, and RR23940 Kansas and UL1 RR025008 Emory, UL1 RR025780 Colorado, UL1 RR024150 Mayo, UL1 RR025752 Tufts, and UL1 RR024992 Washington University). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCRR. Study medication for both trials was provided by Boehringer-Ingelheim Pharmaceuticals (telmisartan and matched placebo) and Merck & Co. (lisinopril). The Polycystic Kidney Disease Foundation provided financial support and recruitment assistance for the enrollment phase of HALTPKD. Results presented in this manuscript have not been published previously, except in abstract form.
Publisher Copyright:
© 2018 International Society of Nephrology
PY - 2018/5
Y1 - 2018/5
N2 - Introduction: The high burden of cardiovascular morbidity and mortality in autosomal dominant polycystic kidney disease (ADPKD) is related to development of hypertension and left ventricular hypertrophy. Blood pressure reduction has been shown to reduce left ventricular mass in ADPKD; however, moderators and predictors of response to lower blood pressure are unknown. Methods: This was a post hoc cohort analysis of HALT PKD study A, a randomized placebo controlled trial examining the effect of low blood pressure and single versus dual renin−angiotensin blockade in early ADPKD. Participants were hypertensive ADPKD patients 15 to 49 years of age with estimated glomerular filtration rate (eGFR) > 60 ml/min per 1.73 m2 across 7 centers in the United States. Predictors included age, sex, baseline eGFR, systolic blood pressure, total kidney volume, serum potassium, and urine sodium, potassium, albumin, and aldosterone. Outcome was left ventricular mass index (LVMI) measured using 1.5-T magnetic resonance imaging at months 0, 24, 48, and 60. Results: Reduction in LVMI was associated with higher baseline systolic blood pressure and larger kidney volume regardless of blood pressure control group assignment (P < 0.001 for both). Male sex and baseline eGFR were associated with a positive annual slope in LVMI (P < 0.001 and P = 0.07, respectively). Conclusion: Characteristics associated with higher risk of progression in ADPKD, including higher systolic blood pressure, larger kidney volume, and lower eGFR are associated with improvement in LVMI with intensive blood pressure control, whereas male sex is associated with a smaller slope of reduction in LVMI.
AB - Introduction: The high burden of cardiovascular morbidity and mortality in autosomal dominant polycystic kidney disease (ADPKD) is related to development of hypertension and left ventricular hypertrophy. Blood pressure reduction has been shown to reduce left ventricular mass in ADPKD; however, moderators and predictors of response to lower blood pressure are unknown. Methods: This was a post hoc cohort analysis of HALT PKD study A, a randomized placebo controlled trial examining the effect of low blood pressure and single versus dual renin−angiotensin blockade in early ADPKD. Participants were hypertensive ADPKD patients 15 to 49 years of age with estimated glomerular filtration rate (eGFR) > 60 ml/min per 1.73 m2 across 7 centers in the United States. Predictors included age, sex, baseline eGFR, systolic blood pressure, total kidney volume, serum potassium, and urine sodium, potassium, albumin, and aldosterone. Outcome was left ventricular mass index (LVMI) measured using 1.5-T magnetic resonance imaging at months 0, 24, 48, and 60. Results: Reduction in LVMI was associated with higher baseline systolic blood pressure and larger kidney volume regardless of blood pressure control group assignment (P < 0.001 for both). Male sex and baseline eGFR were associated with a positive annual slope in LVMI (P < 0.001 and P = 0.07, respectively). Conclusion: Characteristics associated with higher risk of progression in ADPKD, including higher systolic blood pressure, larger kidney volume, and lower eGFR are associated with improvement in LVMI with intensive blood pressure control, whereas male sex is associated with a smaller slope of reduction in LVMI.
KW - autosomal dominant polycystic kidney disease
KW - hypertension
KW - left ventricular hypertrophy
KW - left ventricular mass index
UR - http://www.scopus.com/inward/record.url?scp=85044723645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044723645&partnerID=8YFLogxK
U2 - 10.1016/j.ekir.2017.12.011
DO - 10.1016/j.ekir.2017.12.011
M3 - Article
AN - SCOPUS:85044723645
VL - 3
SP - 619
EP - 624
JO - Kidney International Reports
JF - Kidney International Reports
SN - 2468-0249
IS - 3
ER -